Skip to content
TrackPodcasts
societyAug 16, 202355:26pending

84. Will DMT be a medicine in the UK? with Dr Carol Routledge

Get every episode summarized

Each time The Drug Science Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

About this episode

Join us for an insightful episode featuring Dr. Carol Routledge, a distinguished senior scientist and the Chief Medical and Scientific Officer at Small Pharma Labs. Dr. Routledge takes us on a journey through her remarkable career path that ultimately led her to work at Small Pharma. With a wealth of experience in both preclinical and clinical settings, she has delved into psychiatric and neurological indications, honing her expertise in understanding and treating mental health disorders.

In this conversation, Dr. Carol Routledge draws upon her extensive clinical and psychedelic research background to shed light on the latest developments in DMT research and psychedelic integration therapy. With her profound insights, we explore the potential of these groundbreaking approaches to become formal medicines, revolutionizing the field of mental health treatment.

Tune in as Dr. Carol Routledge shares her passion for advancing mental health treatments through innovative research.

 

DMT 

Depression

Serotonin

Nor adrenaline 

Small Pharma

Chris Timmermann - Human brain effects of DMT assessed via EEG-fMRI

CMC 

British technology group (BTG)

SSRI 

Psychedelic experience

Alzheimers research uk 

★ Support this podcast ★

Hosts & guests

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

84. Will DMT be a medicine in the UK? with Dr Carol Routledge

The Drug Science Podcast

0:00
55:26

More episodes

More from The Drug Science Podcast

View all episodes →